GH Research PLC(GHRS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.99 | Insider Own | 25.83% | Shs Outstand | 68.6M | Perf Week | 15.44% |
| Market Cap | 1.43B | Forward P/E | - | EPS next Y | -53.19% | Insider Trans | - | Shs Float | 50.9M | Perf Month | -8.75% |
| Enterprise Value | 1.07B | PEG | - | EPS next Q | -0.31 | Inst Own | 70.1% | Short Float | 3.95% | Perf Quarter | -26% |
| Income | -0.06B | P/S | - | EPS this Y | -51.26% | Inst Trans | 10.49% | Short Ratio | 6.76 | Perf Half Y | 0.72% |
| Sales | 0.00B | P/B | 3.98 | EPS next 5Y | - | ROA | -18.16% | Short Interest | 2.01M | Perf YTD | 64.25% |
| Book/sh | 5.24 | P/C | 3.95 | EPS past 3/5Y | -22.35% -162.03% | ROE | -18.79% | 52W High | -33.65% ($31.44) | Perf Year | 66.35% |
| Cash/sh | 5.28 | P/FCF | - | Sales past 3/5Y | - | ROIC | -17.32% | 52W Low | 73.26% ($12.04) | Perf 3Y | 180% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -33.76% | Gross Margin | - | Volatility(W/M) | 6.59% 5.67% | Perf 5Y | -17.58% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.19 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 28.7 | EPS Q/Q | -52.04% | Profit Margin | - | RSI (14) | 47.96 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 28.7 | Sales Q/Q | - | SMA20 | 5.38% ($19.8) | Beta | 1.3 | Target Price | $41.7 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -13.29% ($24.06) | Rel Volume | 1.03 | Prev Close | $21.5 |
| Employees | 73 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 24.34% - | SMA200 | -3.19% ($21.55) | Avg Volume(3M) | 0.30M | Price | $20.86 |
| IPO | 2021/6/25 | Option/Short | Yes/Yes | Trades | 3195 | Volume | 305,421 | Change | -2.98% |
🧠 GH Research (GHRS) is a clinical-stage biotech developing mebufotenin-based novel drugs, with treatment-resistant depression as its core target. Building on its inhaled lead candidate, the company is pursuing label expansion into bipolar II depression and postpartum depression. With no revenue and a research-and-development-driven structure, clinical data and regulatory progress are the key drivers of its corporate value.
Over the past 1 year, roughly in the middle
34% below its 1-year high.
Traded about as much as usual. That is 103% of its average volume.
GHRS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -51.3% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -17.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 70.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #132 of 597 in the industry
Based on market cap of $1B.
FAQ
What kind of company is GHRS?
GHRS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GHRS?
The market cap of GHRS is approximately $1.4B, ranking 2,323 within its sector.
What is the 52-week high and low for GHRS?
GHRS has recorded a 52-week high of $31.44 and a low of $12.04.
